Pabliximab before surgery for head and neck cancer
Part of Cancer clinical trials.
This trial tests a drug called Pabliximab given before surgery for head and neck cancer. It aims to see if it can help shrink tumors and improve outcomes for people with a specific type of cancer that can be removed surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of head and neck cancer that can be removed with surgery.
- Your cancer is at a stage that has not spread to other parts of the body.
- You have not had certain other cancer treatments before.
- You do not have a serious autoimmune disease or other uncontrolled health problems.
- Your liver, kidney, and blood counts are within a safe range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests whether adding a PD-L1 antibody (Adabelimab) to standard chemotherapy before surgery can help treat advanced head and neck squamous cell carcinoma. It is for people who have not had treatment for this cancer before and are well enough to undergo the therapy.
This trial tests a combination of two drugs—an immunotherapy (PD-1 inhibitor) and a targeted therapy (cetuximab)—given before surgery to shrink advanced head and neck cancers. The goal is to see if this approach can lower the risk of the cancer coming back.
This trial tests giving a combination of targeted immunotherapy and chemotherapy before surgery for people with advanced head and neck cancer (stage 3 or 4a). The goal is to see if this pre-treatment can shrink tumors and improve outcomes.
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.